Malnutrition and severe dehydration can develop when persistent nausea, vomiting, delayed gastric emptying, or intestinal dysfunction interfere with normal food and fluid intake
For type 2 diabetes, NICE guidance (NG28) recommends GLP-1 RAs based on individual factors including comorbidities, prior treatments, and HbA1c targets
Developed by Eli Lilly, this experimental drug targets multiple pathways in the body, setting it apart from other medications currently available
The triple mechanism of action is hypothesised to produce a more pronounced and complementary effect on body weight and metabolic function than single or dual receptor approaches
Possible Side Effects Tirzepatide may cause: Nausea Constipation Diarrhea Decreased appetite Temporary fatigue Gradual dose titration improves tolerability
The enhanced efficacy of tirzepatide for weight loss compared to semaglutide raises the question of whether similar enhancement exists for alcohol-related outcomes